Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| B1801035 | Other Identifier | Alias Study Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Psoriasis is a chronic, often severe, autoimmune condition that affects approximately 2% of the world's population. The epidemiology of pediatric psoriasis has not been well documented and no treatment guidelines exist for pediatric psoriasis.
Etanercept is a biologic drug and has been licensed for the treatment of chronic severe plaque psoriasis in children and adolescents (6-17 years of age) who are inadequately controlled by or are intolerant to, other systemic therapies or phototherapies. Although the long-term safety and efficacy of etanercept in children with juvenile idiopathic arthritis (JIA) has been studied and the short-term safety profile of etanercept in both JIA and pediatric psoriasis appears similar, there is limited data available about the long-term effects of etanercept in pediatric psoriasis, especially with respect to malignancy. The aim of this study is to assess the safety and effectiveness of etanercept for the treatment of pediatric psoriasis in Europe. Patients aged <=17 with plaque psoriasis diagnosed by a dermatologist will be invited to participate in the registry only after a clinical decision has been made to prescribe etanercept. The safety of the drug and how well the drug works will be evaluated during the follow-up period. The follow-up period will last 5 years and patients will be followed up every 3 months for the first 2 years and every 6 months for the next 3 years or until the end of study.
Non-probability sample
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | pediatric patients with plaque psoriasis on etanercept |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Etanercept | Drug | Expected duration of 24 weeks as one course |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Serious Infections, Opportunistic Infections of Interest and Malignancies: Prospective Participants | Serious infections were defined as any infections those were life-threatening or resulted in disability, infections requiring intravenous antibiotic treatment and hospitalisation. Opportunistic infections of interest included protocol-specified infections due to bacteria: Salmonella bacteremia, Campylobacteriosis, Shigellosis, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium kansasii, Syphilis, Pseudomonas aeruginosa, Acinetobacter baumannii, Listeriosis, Nocardiosis, Legionellosis, Actinomycosis, Bartonellosis; Fungal: Aspergillosis, Invasive Candida albicans, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Blastomycosis, Paracoccidioidomycosis, Sporotrichosis, Penicilliosis, Zygomycosis and Pneumocystosis; Protozoans: Cryptosporidiosis, Isosporiasis, Microsporidiosis, Acanthamoebiasis, Toxoplasmosis, Trypanosomiasis and Leishmaniasis; Viral: Cytomegalovirus, John Cunningham Virus, Disseminated or central nervous system herpes zoster, Kaposi's sarcoma and BK virus. | Baseline up to 5 years |
| Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Prospective Participants | An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events. | Baseline up to 28 days after last dose of study drug (up to 61 months) |
| Number of Participants Who Discontinued From Etanercept During Initial Treatment Period: Prospective Participants | Initial treatment period is defined as the period during which participants received Etanercept treatment for a duration of at least 24 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of Subsequent Etanercept Treatment After Completion of Initial Treatment Period | Week 24 up to Week 216 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
dermatology clinics
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centre Hospitalier Victor Dupouy / Service de Dermatologie | Argenteuil | 95107 | France | |||
| CHRU Tours Hopital Trousseau |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Etanercept | Participants who were diagnosed with plaque psoriasis and on routine treatment of etanercept as per standard clinical practice were enrolled in this study and observed for approximately 5 years. Participants were observed for every 3 months during the first 2 years of the study and every 6 months thereafter for 3 years. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| SAP | No | Yes | No | Statistical Analysis Plan | Feb 12, 2019 | Aug 15, 2019 |
Not provided
Not provided
Not provided
| Baseline up to 24 weeks |
| Number of Participants Who Discontinued From Etanercept After Initial Treatment Period: Prospective Participants | Initial treatment period is defined as the period during which participants received Etanercept treatment for a duration of at least 24 weeks. | Week 24 up to Week 216 |
| Percentage of Participants Who Required Subsequent Treatment With Etanercept or Other Systemic Therapies After Completion of Initial Treatment Period: Prospective Participants | Participants those who completed the initial treatment period of at least 24 weeks and entered the follow up period, and during the follow up period who required subsequent treatment with etanercept or other systemic therapies were reported. | Week 24 up to Week 216 |
| Chambray-lès-Tours |
| 37170 |
| France |
| CHU de Nantes - Hôtel Dieu | Nantes | 44093 | France |
| CH Quimper Cornouaille | Quimper | 29000 | France |
| Charite Universitaetsmedizin Berlin | Berlin | 10117 | Germany |
| Universitaetsklinik Koeln | Cologne | 50937 | Germany |
| Universitaetsklinik Carl Gustav Carus | Dresden | 01307 | Germany |
| Hautklinik Universitaetsklinikum Erlangen | Erlangen | 91052 | Germany |
| Universitätsklinikum Essen | Essen | 45122 | Germany |
| J W Goethe Universitaet Frankfurt | Frankfurt am Main | 60590 | Germany |
| Kath. Kinderkrankenhaus Wilhelmstift | Hamburg | 53757 | Germany |
| Kinderklinik der Johannes-Gutenberg Universitat Mainz | Mainz | 55101 | Germany |
| Asklepios Klinik Sankt Augustin GmbH | Sankt Augustin | 53757 | Germany |
| Andreas Syngros Hospital | Athens | 16121 | Greece |
| University of Athens, Andreas Syngros Hospital | Athens | 16121 | Greece |
| Skin and Venereal Diseases' Hospital | Thessaloniki | 54643 | Greece |
| Heim Pal Children's Hospital | Budapest | 1089 | Hungary |
| Universita degli Studi di Napoli Federico II | Naples | 80131 | Italy |
| Universita degli Studi di Napoli | Naples | 80131 | Italy |
| University of Padova | Padova | 35128 | Italy |
| ARNAS Civico Di Gristina M Ascoli | Palermo | 90127 | Italy |
| Università Cattolica del Sacro Cuore Policlinico A. | Roma | 00168 | Italy |
| Ospitale Alfredo Fiorini | Terracina | 04019 | Italy |
| UMC St Radbound | Nijmegen | 6500 HB | Netherlands |
| Erasmus MC | Rotterdam | 3000 CA | Netherlands |
| Hospital Santa Maria | Lisbon | 1649-028 | Portugal |
| Hospital de la Santa Cruz y San Pablo | Barcelona | 08025 | Spain |
| Hospital Parc Tauli | Barcelona | 08208 | Spain |
| Hospital Universitario La Paz | Madrid | 28046 | Spain |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Analysis population included all enrolled participants who were documented as having received at least 1 dose of etanercept.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Etanercept | Participants who were diagnosed with plaque psoriasis and on routine treatment of etanercept as per standard clinical practice were enrolled in this study and observed for approximately 5 years. Participants were observed for every 3 months during the first 2 years of the study and every 6 months thereafter for 3 years. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | Years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Race/Ethnicity, Customized | For Unknown: as per local regulations of France and Portugal, race/ethnicity should not be disclosed hence 11 participants from France and Portugal captured as Unknown. | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Serious Infections, Opportunistic Infections of Interest and Malignancies: Prospective Participants | Serious infections were defined as any infections those were life-threatening or resulted in disability, infections requiring intravenous antibiotic treatment and hospitalisation. Opportunistic infections of interest included protocol-specified infections due to bacteria: Salmonella bacteremia, Campylobacteriosis, Shigellosis, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium kansasii, Syphilis, Pseudomonas aeruginosa, Acinetobacter baumannii, Listeriosis, Nocardiosis, Legionellosis, Actinomycosis, Bartonellosis; Fungal: Aspergillosis, Invasive Candida albicans, Coccidioidomycosis, Cryptococcosis, Histoplasmosis, Blastomycosis, Paracoccidioidomycosis, Sporotrichosis, Penicilliosis, Zygomycosis and Pneumocystosis; Protozoans: Cryptosporidiosis, Isosporiasis, Microsporidiosis, Acanthamoebiasis, Toxoplasmosis, Trypanosomiasis and Leishmaniasis; Viral: Cytomegalovirus, John Cunningham Virus, Disseminated or central nervous system herpes zoster, Kaposi's sarcoma and BK virus. | Prospective Participants: participants who started etanercept within 30 days before the enrollment date or any time after enrollment date. This outcome measure was planned to be analyzed in prospective participants only. | Posted | Count of Participants | Participants | Baseline up to 5 years |
|
|
| ||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Prospective Participants | An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events. | Prospective Participants: participants who started etanercept within 30 days before the enrollment date or any time after enrollment date. This outcome measure was planned to be analyzed in prospective participants only. | Posted | Count of Participants | Participants | Baseline up to 28 days after last dose of study drug (up to 61 months) |
| ||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants Who Discontinued From Etanercept During Initial Treatment Period: Prospective Participants | Initial treatment period is defined as the period during which participants received Etanercept treatment for a duration of at least 24 weeks. | Prospective Participants: participants who started etanercept within 30 days before the enrollment date or any time after enrollment date. This outcome measure was planned to be analyzed in prospective participants only. | Posted | Count of Participants | Participants | Baseline up to 24 weeks |
|
| |||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants Who Discontinued From Etanercept After Initial Treatment Period: Prospective Participants | Initial treatment period is defined as the period during which participants received Etanercept treatment for a duration of at least 24 weeks. | Prospective Participants: participants who started etanercept within 30 days before the enrollment date or any time after enrollment date. This outcome measure was planned to be analyzed in prospective participants only. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. | Posted | Count of Participants | Participants | Week 24 up to Week 216 |
|
| |||||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants Who Required Subsequent Treatment With Etanercept or Other Systemic Therapies After Completion of Initial Treatment Period: Prospective Participants | Participants those who completed the initial treatment period of at least 24 weeks and entered the follow up period, and during the follow up period who required subsequent treatment with etanercept or other systemic therapies were reported. | Prospective Participants: participants who started etanercept within 30 days before the enrollment date or any time after enrollment date. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure and "Number Analyzed" signifies the participants evaluable at specific rows. | Posted | Number | percentage of participants | Week 24 up to Week 216 |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Duration of Subsequent Etanercept Treatment After Completion of Initial Treatment Period | Analysis population included all enrolled participants who were documented as having received at least 1 dose of etanercept. Here, "Overall Number of Participants Analyzed" signifies participants evaluable for this outcome measure. | Posted | Mean | Standard Deviation | weeks | Week 24 up to Week 216 |
|
|
Baseline up to 28 days after last dose of study drug (up to 61 months)
Same event may appear as both an AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as non-serious in another participant or 1 participant may have experienced both a serious and non-serious event during study.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Etanercept | Participants who were diagnosed with plaque psoriasis and on routine treatment of etanercept as per standard clinical practice were enrolled in this study and observed for approximately 5 years. Participants were observed for every 3 months during the first 2 years of the study and every 6 months thereafter for 3 years. | 0 | 72 | 11 | 72 | 44 | 72 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Angina pectoris | Cardiac disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Drug ineffective | General disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Hepatic steatosis | Hepatobiliary disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Chronic tonsillitis | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Cholesteatoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v14.0 | Non-systematic Assessment |
| |
| Paraesthesia | Nervous system disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Anorexia nervosa | Psychiatric disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Erythema nodosum | Skin and subcutaneous tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Erythrodermic psoriasis | Skin and subcutaneous tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Psoriasis | Skin and subcutaneous tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Lymphadenopathy | Blood and lymphatic system disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Conjunctivitis | Eye disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Abdominal pain | Gastrointestinal disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Abdominal pain upper | Gastrointestinal disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Irritable bowel syndrome | Gastrointestinal disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Drug ineffective | General disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Injection site erythema | General disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Injection site pain | General disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Injection site reaction | General disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| No adverse event | General disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Acute tonsillitis | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Bronchitis | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Ear infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Eczema infected | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Enterovirus infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Gastroenteritis viral | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Gastrointestinal infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Herpes simplex | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Hordeolum | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Otitis media | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Pharyngitis | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Respiratory tract infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Respiratory tract infection viral | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Rhinitis | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Scarlet fever | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Streptococcal infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Tonsillitis | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Viral infection | Infections and infestations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Contusion | Injury, poisoning and procedural complications | MedDRA v14.0 | Non-systematic Assessment |
| |
| Excoriation | Injury, poisoning and procedural complications | MedDRA v14.0 | Non-systematic Assessment |
| |
| Muscle rupture | Injury, poisoning and procedural complications | MedDRA v14.0 | Non-systematic Assessment |
| |
| Skeletal injury | Injury, poisoning and procedural complications | MedDRA v14.0 | Non-systematic Assessment |
| |
| Sunburn | Injury, poisoning and procedural complications | MedDRA v14.0 | Non-systematic Assessment |
| |
| Alanine aminotransferase increased | Investigations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Eosinophil count increased | Investigations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Liver function test abnormal | Investigations | MedDRA v14.0 | Non-systematic Assessment |
| |
| Hypercholesterolaemia | Metabolism and nutrition disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Exostosis | Musculoskeletal and connective tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Skin papilloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA v14.0 | Non-systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Hypoaesthesia | Nervous system disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Migraine | Nervous system disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Transient global amnesia | Nervous system disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Pregnancy | Pregnancy, puerperium and perinatal conditions | MedDRA v14.0 | Non-systematic Assessment |
| |
| Somatoform disorder neurologic | Psychiatric disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Proteinuria | Renal and urinary disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Acne | Skin and subcutaneous tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Erythema | Skin and subcutaneous tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Psoriasis | Skin and subcutaneous tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Vitiligo | Skin and subcutaneous tissue disorders | MedDRA v14.0 | Non-systematic Assessment |
| |
| Venous thrombosis | Vascular disorders | MedDRA v14.0 | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
| SAP_000.pdf |
| Prot | Yes | No | No | Study Protocol | Jul 1, 2014 | Aug 15, 2019 | Prot_001.pdf |
| ID | Term |
|---|---|
| D011565 | Psoriasis |
| ID | Term |
|---|---|
| D017444 | Skin Diseases, Papulosquamous |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068800 | Etanercept |
| ID | Term |
|---|---|
| D007141 | Immunoglobulin Fc Fragments |
| D007128 | Immunoglobulin Fragments |
| D010446 | Peptide Fragments |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D007127 | Immunoglobulin Constant Regions |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D018124 | Receptors, Tumor Necrosis Factor |
| D018121 | Receptors, Cytokine |
| D011971 | Receptors, Immunologic |
| D011956 | Receptors, Cell Surface |
| D008565 | Membrane Proteins |
Not provided
Not provided
| Other Asian |
|
| Other |
|
| Unknown |
|
| Title | Measurements |
|---|---|
|
| Units | Counts |
|---|
| Participants |
|
|
|
|
|
|